Table I.

Characteristics of 10 studies included in the meta-analysis.

First author	Year	Disease	circRNA used for detection	Case no.	Control no.	Region	TP	FP	FN	TN	IF	(Refs.)
Li et al	2015	Gastric cancer	hsa_circ_002059	101	101	China	82	38	19	63	2.799	(18)
Qin et al	2016	Hepatocellular carcinoma	hsa_circ_0001649	89	89	China	72	28	17	61	1.736	(19)
Wang et al	2015	Colorectal cancer	hsa_circ_001988	31	31	China	21	8	10	23	1.581	(20)
Shang et al	2016	Hepatocellular carcinoma	hsa_circ_0005075	30	30	China	25	3	5	27	2.133	(21)
Chen et al	2017	Gastric cancer	hsa_circ_0000190	104	104	China	75	30	29	74	2.799	(22)
Huang et al	2017	Gastric cancer	hsa_circ_0000745	60	60	China	51	33	9	27	3.365	(23)
Fu et al	2017	Hepatocellular carcinoma	hsa_circ_0003570	107	107	China	48	14	59	93	1.521	(24)
Yin et al	2017	Breast cancer	hsa_circ_0001785	20	20	China	16	5	4	15	2.871	(25)
		Breast cancer	hsa_circ_0108942	20	20	China	16	10	4	10	2.871
		Breast cancer	hsa_circ_0068033	20	20	China	14	8	6	12	2.871
Yao et al	2017	Hepatocellular carcinoma	cirZKSCAN1	102	102	China	84	28	18	74	5.314	(26)
Zhao et al	2017	Gastric cancer	hsa_circ_0000181	115	115	China	62	17	53	98	1.521	(27)

TP, true-positive; FP, false-positive; FN, false-negative; TN, true-negative; IF, impact factor; circRNA, circular RNA.